Study Comparing Treatment Adherence With Ribociclib and Aromatase Inhibitors Using a Mobile App in Patients With Stage II-III HR HER2-Negative Breast Cancer

What this Trial Is About

Researchers are evaluating the impact of a mobile application on treatment adherence in patients with stage II-III hormone receptor positive HR HER2-negative breast cancer. The study aims to see if using this app can help patients stick to their adjuvant therapy with ribociclib combined with an aromatase inhibitor AI by providing information on relapse risks and managing side effects. Participants include patients receiving adjuvant ribociclib plus AI therapy in routine clinical practice, divided into two groups those who use the web application and those who do not. The app is designed to support patients throughout their treatment, with observations made over 12 months and longer-term follow-up up to 36 months for user engagement and satisfaction. During the study, researchers will monitor the number of patients remaining on ribociclib plus AI treatment over 12 months. They will also assess app usage details such as session frequency and duration, patient and oncologist satisfaction, quality of life, treatment satisfaction, dose intensity, and adverse events. Data on patient demographics and tumor characteristics will be collected at baseline, with ongoing evaluations at multiple time points up to three years.

Implementation Study to Describe and Compare Retention Rate and Adherence to Adjuvant Therapy With Ribociclib With and Without Usage of Mobile Application in Patients With HR+ HER2-negative Stage II and III Breast Cancer in Real-world Practice